Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 109 results for paclitaxel

  1. Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)

    Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.

    Technology appraisal guidance
    Published
    29 June 2022
    View recommendations

    Sections for TA801

  2. Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381

    In development [GID-TA11461] Expected publication date: 16 April 2025

    Technology appraisal guidance
    In development

  3. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415

    In development [GID-TA11503] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  5. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA904

  6. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development [GID-TA11340] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  7. Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)

    Evidence-based recommendations on trastuzumab for treating advanced breast cancer in adults.

    Technology appraisal guidance
    Published
    15 March 2002
    View recommendations

    Sections for TA34

  8. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

    Technology appraisal guidance
    Published
    28 October 2009
    View recommendations

    Sections for TA183

  9. Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]

    In development [GID-TA10907] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  10. Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)

    Evidence-based recommendations on nivolumab (Opdivo) for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.

    Technology appraisal guidance
    Published
    4 July 2018
    View recommendations

    Sections for TA530

  11. Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

    In development [GID-TA10252] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  12. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development [GID-TA11023] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  13. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]

    In development [GID-TA10784] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  14. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  15. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development